Clinical Trials


Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults

This study has been completed
United Biomedical

Information provided by (Responsible Party)
United Biomedical Identifier

First received: June 7, 2010
Last updated: July 7, 2011
Last Verified: July 2011
History of Changes


The purpose of this Phase I study is to determine whether the antibody (UB-421), targeting the HIV-1 receptor on the CD4 molecule (domain 1) of T-lymphocytes and monocytes, is safe and well tolerated when administered to asymptomatic HIV-1 infected adults by intravenous infusion and to assess pharmacokinetic parameters of the antibody in blood and on cells. The neutralizing activity of UB-421 blocks HIV-1 from binding to its receptor on CD4-positive cells; thus, UB-421 functions as an immunotherapeutic intervention to prevent HIV-1 infection.

Condition Intervention Phase
HIV-1 Infection in Adults (Asymptomatic)

Drug : Antibody UB-421
Phase 1

Study Type: Interventional
Study Design: Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults

Further study details as provided by United Biomedical:

Primary Outcome Measures

  • To evaluate safety and tolerability of a single intravenous infusion at escalating doses of UB-421. [ Time Frame: Screen, treatment & follow-up: 62 to 90 days ]
Secondary Outcome Measures:
  • To determine pharmacokinetic parameters of a single intravenous infusion at escalating doses of UB-421. [ Time Frame: Screen, treatment & follow-up: 62 to 90 days ]

Enrollment: 20
Study Start Date: May 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Antibody (UB-421)

Drug: Antibody UB-421

Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.



Ages Eligible for Study: 20 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • Asymptomatic, treatment-naive, HIV-1 seropositive
  • CD4+ T cell count >350 cells/cubic millimeter
  • HIV-1 viral load >5,000 copies/mL
  • Other inclusion criteria apply

Exclusion Criteria:
  • Active infection requiring immediate therapy (except HIV-1)
  • Prior participation in any HIV vaccine trial
  • Previous exposure to a monoclonal antibody
  • Use of immunomodulating drugs or systemic chemotherapy
  • Other exclusion criteria apply

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01140126


Taipei Veterans General Hospital (TVGH)
Taipei City, Beitou District, Taiwan, 11217
Kaohsiung Veterans General Hospital (KVGH)
Kaohsiung City, Zuoying District, Taiwan, 81362

Sponsors and Collaborators

United Biomedical


Principal Investigator: Wing Wai Wong, M.D. Taipei Veterans General Hospital (TVGH), Taiwan
Principal Investigator: Hung Chin Tsai, M.D. Kaohsiung Veterans General Hospital (KVGH), Taiwan
More Information

More Information

Additional Information:

S Lynn and CY Wang. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection. U.S. Patent No. 7,501,494

Responsible Party: Wing Wai Wong, M.D., Taipei Veterans General Hospital (TVGH), Taiwan Identifier: NCT01140126   History of Changes  
Other Study ID Numbers: UBI Protocol A101  
  Protocol A101-HIV  
Study First Received: June 7, 2010  
Last Updated: July 7, 2011  

Keywords provided by United Biomedical:

HIV-1, CD4, antibody, immunotherapy

Additional relevant MeSH terms:
Antibodies processed this data on May 24, 2020
This information is provided by